Workflow
中国医疗集团(08225) - 2021 - 中期财报
C HEALTH GPC HEALTH GP(HK:08225)2021-08-13 13:49

Financial Performance - For the six months ended June 30, 2021, the group recorded revenue of approximately RMB 48,093,000, an increase of about 14.44% compared to the same period in 2020[4] - The group reported a profit before tax of approximately RMB 27,977,000 for the six months ended June 30, 2021, representing an increase of approximately 9.56% year-on-year[5] - Basic earnings per share for the six months ended June 30, 2021, were approximately RMB 2.33 cents, up about 4.95% from the same period in 2020[6] - The group’s net profit for the six months ended June 30, 2021, was RMB 23,188,000, compared to RMB 22,047,000 for the same period in 2020[10] - The total revenue for the six months ended June 30, 2021, increased by 14.44% compared to the same period in 2020, with PMS revenue growing approximately 16.80%[24] - The net profit attributable to the owners of the company for the period was approximately RMB 23,188,000, compared to RMB 22,047,000 in 2020[27] Assets and Liabilities - The group’s total assets less current liabilities as of June 30, 2021, amounted to RMB 142,435,000, compared to RMB 118,675,000 as of December 31, 2020[12] - The group’s cash and cash equivalents at the end of the period were RMB 11,582,000, down from RMB 16,193,000 at the beginning of the period[14] - The net cash used in operating activities for the six months ended June 30, 2021, was RMB (2,344,000), compared to RMB 3,113,000 for the same period in 2020[14] - Trade receivables increased to RMB 116,367,000 as of June 30, 2021, from RMB 86,056,000 as of December 31, 2020[12] - As of June 30, 2021, the group's net current assets were approximately RMB 140,802,000, an increase from RMB 116,924,000 as of December 31, 2020[51] - The group had no borrowings as of June 30, 2021, compared to secured bank borrowings of approximately RMB 1,500,000 as of December 31, 2020[51] Expenses and Costs - Administrative expenses rose by 123.40% compared to the same period in 2020, amounting to RMB (5,853,000) for the six months ended June 30, 2021[25] - The total administrative and employee costs for the period amounted to approximately RMB 10,617,000, up from RMB 7,384,000 in the previous year[50] - The income tax expense for the period was RMB 4,789,000, compared to RMB 3,489,000 in 2020[30] Dividends - The board of directors recommended not to declare any dividend for the six months ended June 30, 2021[7] - The company did not recommend any dividend payment for the period, consistent with the previous year[31] - No dividends were recommended for the six months ended June 30, 2021[53] Employee Information - The group had a total of 85 employees as of June 30, 2021, an increase from 82 employees at the end of 2020[73] - Employee compensation, including salaries and bonuses, amounted to approximately RMB 4,764,000 for the period, consistent with the previous year[73] Corporate Governance - The company adhered to the corporate governance practices as per the GEM Listing Rules, with a noted deviation regarding the separation of the roles of Chairman and CEO[110] - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[112] - As of the report date, the company maintained sufficient public float as per the information available to the board[114] - The company’s board consists of two executive directors and three independent non-executive directors as of the report date[115] Stock Options - The company has a stock option plan in place, granting options to qualified participants[74] - The stock option plan aims to incentivize qualified participants for their contributions to the group's long-term development[91] - The total number of stock options granted during the period was 14,650,000, with a remaining balance of 25,500,000 as of June 30, 2021[105] - The exercise price for the stock options granted in March 2021 was HKD 0.504, with a total of 5,070,000 options granted during this period[105] - The maximum number of shares available for subscription under the stock option plan is 78,087,166 shares, representing 7.85% of the total issued shares as of the interim report date[98] - The maximum number of shares that can be issued to each eligible participant in any 12-month period cannot exceed 1% of the issued shares without shareholder approval[97] Future Plans - The group plans to enhance market promotion capabilities and expand market networks, focusing on a full value chain business model in the local market[52] - The group has established a digital medical service ecosystem, integrating research to rehabilitation[46] Risk Management - The group closely monitors foreign currency risks, with most transactions denominated in RMB, and will hedge as necessary[66] - The board continues to follow a prudent policy to manage cash and maintain strong liquidity to seize future growth opportunities[67] Other Information - There were no significant investments or acquisitions during the period[55][57] - There were no significant subsequent events after June 30, 2021, up to the report date[69] - The company did not engage in any share buybacks, sales, or redemptions during the reporting period[75] - The company has not granted, exercised, canceled, or allowed any other stock options to expire during the reporting period[108]